Download - Report to FNLCR
Report to FNLCRNorman E. Sharpless, MD
May 8, 2018
2
White House OMB
coordinates with
federal agencies
to formulate the
President’s budget
proposal
Congressional
appropriations
committees
consider
President’s
proposal &
prepare legislation
Congress
reconciles &
finalizes
appropriations
legislation & sends
to the President
President signs
the appropriations
bill into law
making funds
available for
NIH & NCI
STEP 1 STEP 2 STEP 3 STEP 4
Appropriations Outlook
FY 2019
3
NCI Appropriations FY 2014-2019 (in millions)
$4,923 $4,950 $5,215 $5,389$5,665
$5,226
$0
$1,000
$2,000
$3,000
$4,000
$5,000
$6,000
$7,000
FY 2014 EnactedAppropriation
FY 2015 EnactedAppropriation
FY 2016 EnactedAppropriation
FY 2017 EnactedAppropriation
FY 2018 ConsolidatedAppropriation Act
FY 2019 President'sBudget
$5,689
Source: NCI Office of Budget and Finance
$5,965 $5,626
Base Appropriation
21st Century Cures Cancer Moonshot
4
Congressional Outreach
5
RPG Pool Trends
FY2013 FY2014 FY2015 FY2016 FY2017
Number of R01
Applications4003 3847 4550 4758 5263
Number of R01
Awards582 578 623 650 650
Success rate
(%)15% 15% 14% 14% 12%
Non-competing
support (%)94% 97% 100% 100% 100%
Total RPG
($B)1.854 1.858 1.927 1.967 2.070
6
Intergovernmental Affairs
7
Scott Gottlieb Commissioner of FDA
Seema VermaDirector, CMS
Collaborating with FDA and CMS
• Oncology Center of Excellence
• Joint Training
• Data Sharing
• Compliance advice on cell manufacture
• Help with NGS coverage decision
• Data Sharing
• Discussions over enhanced coverage of
clinical trials
8
Collaborating with DoD and VA
9
Collaborating with DoE: RAS Modeling
Collaborating with DoE: SEER Natural Language Processing EHR Mining
SEER Cancer Information
Resource
Surveillance data captured on each cancer patient
Pathology Molecular
CharacterizationRadiation
Initial
Treatment
Survival, Progression,
Patient Outcomes
Subsequent
Treatment
Support development of new
diagnostics and treatments
through a population-based
infrastructure
Understand treatments and
outcomes in the “real
world”
10
Genome
Demographics
11
President’s Cancer Panel ReportMarch 2018
12
New NCAB Working Groups
• Deborah Bruner, RN, PhD
Emory University
• Satish Gopal, MD
UNC Chapel Hill
• Elizabeth Jaffee, MD
Johns Hopkins University
• Mel Billingsley, PhD
Pennsylvania State
University
• Mia Levy, MD
Vanderbilt University
• Charles Sawyers, MD
Memorial Sloan Kettering
Cancer Center
Global Health SBIR / STTR Informatics
13
Cancer Moonshot
21st Century Cures Act
Authorized Funding for
Cancer Moonshot
Dec. 2016
NCI Teams, Leaders & BSA Develop
& Review Scientific Proposals Aligned
with BRP Recommendations
Apr.-Jun. 2017
$300M Awarded
FY2018 FOAs Released
Fall 2017
Blue Ribbon Panel
Recommendations
Sept. 2016
14
Cancer Moonshot FOAs
• Close to 50
Funding Opportunity
Announcements
to date and more to
come
• 6 intramural initiatives
• Requirements related to
data sharing and health
disparities/ underserved
populations
15
17
Cancer Immune
Monitoring Analysis
Centers (CIMACs)
AbbVie AmgenBoehringer
IngelheimBMS
Genentech Gilead GSK
Janssen Novartis Pfizer
Celgene
Cancer
Immunologic Data
Commons (CIDC)
Dana-Farber
Stanford
Mount Sinai
MD Anderson
Dana-Farber
Cancer
Institute
National Cancer Institute - Division of Cancer Treatment & Diagnosis
Sanofi
Partnership for Accelerating Cancer Therapies (PACT)
18
Two New Immunotherapy Networks
Immuno-Oncology Translational Network
(IOTN, U01)
Pediatric Immunotherapy Discovery and Development Network
(PIDDN, U54)
ADULT CANCERS PEDIATRIC CANCERS
19
Developing New Cell Therapy Facility at FNLCR
Addressing the Growing
Need for Clinical Grade
T-cell Manufacturing
20
Key Focus Areas
Fully realize the power of clinical trials
through innovative design,
administration, and analyses
C L I N I C AL T R I AL S
Support the cancer research enterprise
by focusing on the workforce of cancer
investigators
W O R K F O R C E D E V E L O P M E N T
Reaffirm our commitment to basic
science to drive novel approaches and
technologies
B AS I C S C I E N C E
Increase data aggregation and
interpretation to speed our work
across the cancer enterprise
B I G D ATA
#NCIFuture
21
• Ensure diversity and representation
• Encourage training of the right skills (Ks and Rs)
• Set aside R01 funding for early-stage investigators (ESIs)
• Method to Extend Research in Time (MERIT) – R37
#CancerTrainingWorkforce Training& Development
#NCIFuture
22
• Support the linkage of existing datasets
• Maintain a data ecosystem
• Create common data standards
• Incentivize sharing and aggregation
#BigDataBigData
#NCIFuture
23
Today’s Agenda
• FNL: Current Operations & Future Plans
• National CRYO-EM Facility (NCEF) Update
• Overview of the NCI Experimental Therapeutics Program
• Role of Molecular Pharmacodynamics in both Drug Discovery & Development
• NCI’s Early Therapeutic
Trials Network: How We
Move New Agents Into The
Clinic
• Accelerating Therapeutics
For Opportunities In
Medicine (ATOM) Update
• NCI-DOE Collaborations
Working Group Report
24
RAS
InitiativeCryo-EM
?
www.cancer.gov
www.cancer.gov/espanol